Filter
Period
Filter by
recent search
Showing: 1 – 05 of 152 Regulated Information
–
22 August 2023
22 August 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 33 – 2023
Aggregated presentation by day and by market
–
21 August 2023
21 August 2023
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer
–
16 August 2023
16 August 2023
US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated for the reduction in volume of new heterotopic ossification in…
–
16 August 2023
16 August 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 32 – 2023
Aggregated presentation by day and by market
–
08 August 2023
08 August 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 31 – 2023
Aggregated presentation by day and by market